In the ever-evolving landscape of pharmaceuticals, the debate over regulatory data protection (RDP) is intensifying. As the Belgian Presidency of the Council of the EU approaches its twilight, policymakers are grappling with how to balance the imperatives of fostering pharmaceutical innovation with
The landscape of biopharmaceutical manufacturing in Ireland has recently welcomed an impressive addition with the inauguration of the National Institute for Bioprocessing Research and Training's (NIBRT) new facility. This state-of-the-art establishment in Dublin, conceived with a robust €21 m
In a significant move aimed at boosting the development of cell and gene therapies, Bionova Scientific, a part of the Asahi Kasei Group, has announced an ambitious $100 million investment. This investment will see the creation of a new state-of-the-art plasmid DNA (pDNA) production facility in The
In the rapidly-changing environment of the pharmaceutical industry, the innovative stride of Pharma 4.0 heralds a new era of drug production. This pivotal shift to smart manufacturing aligns with the principles of Industry 4.0, embedding digitalization and cutting-edge technology to meet the
In the dynamic realm of biopharmaceutical investments, the diverging analyst ratings for Can-Fite BioPharma (NYSE: CANF) underscore the complex calculus of betting on drug development firms. The stock analysis firm StockNews.com has planted its flag with a "hold" rating, signaling a
AstraZeneca, the renowned pharmaceutical giant, has unveiled plans to invest $1.5 billion in a cutting-edge antibody drug conjugate (ADC) manufacturing facility in Singapore, marking a significant milestone in the company's history. The state-of-the-art factory is poised to become operational
